(AOF) – Medesis Pharma announces the completion of a capital increase of 440,000 euros. The biotech developing drugs based on a proprietary technology for administering active ingredients in nano micelles via the oral route, specifies that this will include continuing the development of its phase 2 clinical study for the treatment of the disease. of Alzheimer’s. The resulting dilution is 11%. Following this operation, the capital of Medesis Pharma is made up of 4.96 million shares with a par value of 0.50 euros.
Medesis Pharma requested and obtained the opening, on September 29, 2023, of a safeguard procedure with the Montpellier Commercial Court. This can last up to twelve months and leads to the temporary suspension of its financial and tax obligations.
The cash flow as of June 30, 2023 amounted to 139,000 euros, and the resources resulting from this capital increase will allow Medesis Pharma to extend its cash flow horizon until the month of January 2024.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
